Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer

Kohei Yamashita,Masaaki Iwatsuki,Noriko Yasuda-Yoshihara,Takeshi Morinaga,Yosuke Nakao,Kazuto Harada,Kojiro Eto,Junji Kurashige,Yukiharu Hiyoshi,Takatsugu Ishimoto,Yohei Nagai,Shiro Iwagami,Yoshifumi Baba,Yuji Miyamoto,Naoya Yoshida,Jaffer A. Ajani,Hideo Baba

DOI: https://doi.org/10.1038/s41416-020-01138-3

IF: 9.075

2020-10-26

British Journal of Cancer

Abstract:Abstract Background The predictive significance of programmed death ligand 1 (PD-L1) for programmed death 1 (PD-1) inhibitors remains unclear in gastric cancer (GC) due to the dynamic alteration by treatments. We aimed to elucidate the effects of trastuzumab (Tmab) on PD-L1 expression in GC. Methods PD-L1 expression was evaluated by multicolour flow cytometry analysis after co-culturing GG cell lines and immune cells with Tmab. IFN-γ in the co-culture experiments was quantified. Immunohistochemistry (IHC) for PD-L1 expression using clinical samples was also performed to confirm PD-L1 alteration by Tmab. Results PD-L1 expression was significantly upregulated by Tmab in HER2 -amplified GC cell lines co-cultured with peripheral blood mononuclear cells (PBMCs). PD-L1 upregulation by Tmab was also observed in the GC cells co-cultured with NK cells in time-dependent manner, but not with monocytes. IFN-γ concentration in conditioned media from co-cultured PBMCs and NK cells with Tmab was significantly higher and anti-IFN-γ significantly suppress the Tmab-induced PD-L1 upregulation. IHC also suggested PD-L1 upregulation after Tmab treatment. Conclusions Tmab can upregulate PD-L1 expression on GC cells through interaction with NK cells. These results suggest clinical implications in the assessment of the predictive significance of PD-L1 expression for PD-1 inhibitors.

oncology